Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRp.

Bangdi Zhou, Dianming Chen, Tingyan Zhang, Chenggui Song, Xianwu Zhang, Leying Lin, Jiuzhong Huang, Xiaopeng Peng, Yuanchang Liu, Gaorong Wu, Jingyuan Li, Weiming Chen

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2024 Feb

filter terms:

The RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 plays a pivotal role in the life cycle of the novel coronavirus and stands as a significant and promising target for anti-SARS-CoV-2 drugs. Non-nucleoside inhibitors (NNIs), as a category of compounds directed against SARS-CoV-2 RdRp, exhibit a unique and highly effective mechanism, effectively overcoming various factors contributing to drug resistance against nucleoside inhibitors (NIs). This review investigates various NNIs, including both natural and synthetic inhibitors, that closely interacting with the SARS-CoV-2 RdRp with valid evidences from in vitro and in silico studies. Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Citation

Bangdi Zhou, Dianming Chen, Tingyan Zhang, Chenggui Song, Xianwu Zhang, Leying Lin, Jiuzhong Huang, Xiaopeng Peng, Yuanchang Liu, Gaorong Wu, Jingyuan Li, Weiming Chen. Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRp. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2024 Feb;171:116180